Abstract:ID 91703 Poster Board 477 Cancer patients commonly experience neuropathic pain caused by off-target effects of their chemotherapeutic treatments known as chemotherapy-induced peripheral neuropathy (CIPN), or by tumor metastasis to bone known as cancer-induced bone pain (CIBP). There are currently no treatments for either of these cancer-related neuropathies and current clinical regimens focus on symptom management. Current treatments have limited therapeutic windows due to negative side effects associated with utilized therapeutics that include opioids, anti-depressants, and gabapentinoids. A recently synthesized allosteric modulator of the g-protein activated inwardly rectifying potassium channels (GIRK) 1 and 2, known as GAT-1508, may be able to provide effective anti-allodynic effects with an improved therapeutic window. Utilizing CIPN and CIBP preclinical models, we assessed whether GAT-1508 would attenuate cancer-related mechanical allodynia. The CIPN model was induced in male and female C57BL/6 mice via a dosing cycle (8 mg/kg ip, given every other day, 32 mg/kg cumulative) of paclitaxel, a chemotherapeutic agent. The CIBP neuropathic pain model was induced in male and female C3H/HeJ mice, a mouse strain that is syngeneic to the murine fibrosarcoma cell line, NCTC-2472. Following implantation of NCTC-2472 fibrosarcoma cells into the calcaneus bone, mice exhibited mechanical allodynia associated with bone tumor metastasis. Vehicle injection served as a control and the von Frey assay was utilized to assess mechanical allodynia in both models. GAT-1508 (17.8–100 mg/kg, ip) dose-relatedly attenuated CIPN-induced mechanical allodynia (F (1.42, 21.36) = 485.6, p < 0.0001). Similarly, GAT-1508 dose-relatedly attenuated CIBP-induced mechanical allodynia (F 1.3, 9.1) = 22.64, p < 0.001). Additionally, at the highest dose tested (100 mg/kg, i.p.), GAT-1508 did not alter locomotor behavior, including distance ( p = 0.71) and speed ( p = 0.77). GAT-1508 dose-relatedly attenuated mechanical allodynia in both models. Given that no locomotor effects were observed, GAT-1508 may provide therapeutic effects with an improved therapeutic window and limited side-effects. Ultimately, these findings support further development and study of GIRK channel modulation for potential neuropathic pain therapeutics.

Optimization of an assay to measure chemosensory changes that accompany oral cancer

The impact of tumor immunogenicity on cancer pain phenotype using syngeneic oral cancer mouse models

Molecular and Behavioral Changes in Nociception in a Novel Rat Model of Chronic Pancreatitis for the Study of Pain

Targeting TRPV4 Channels for Cancer Pain Relief

Molecular mechanisms of cancer pain

Expression profiles of TRPV1, TRPV4, TLR4 and ERK1/2 in the dorsal root ganglionic neurons of a cancer-induced neuropathy rat model

Tumor necrosis factor alpha secreted from oral squamous cell carcinoma contributes to cancer pain and associated inflammation

Assessment of orofacial nociceptive behaviors of mice with the sheltering tube method: Oxaliplatin-induced mechanical and cold allodynia in orofacial regions

A pilot study to improve pain phenotyping in head and neck cancer patients

Oral Irritation in Patients with Chemosensory Dysfunction

IB4(+) and TRPV1(+) sensory neurons mediate pain but not proliferation in a mouse model of squamous cell carcinoma

Biological Mediators and Partial Regulatory Mechanisms on Neuropathic Pain Associated With Chemotherapeutic Agents

PAR2 on oral cancer cells and nociceptors contributes to oral cancer pain that can be relieved by nanoparticle-encapsulated AZ3451

Oral squamous cell carcinoma-released brain-derived neurotrophic factor contributes to oral cancer pain by peripheral tropomyosin receptor kinase B activation

Neuroimaging uncovers neuronal and metabolic changes in pain modulatory brain areas in a rat model of chemotherapy-induced neuropathy – MEMRI and ex vivo spectroscopy studies

Examining Sodium and Potassium Channel Conductances Involved in Hyperexcitability of Chemotherapy-Induced Peripheral Neuropathy: A Mathematical and Cell Culture-Based Study

Neurotrophin Pathway Receptors NGFR and TrkA Control Perineural Invasion, Metastasis, and Pain in Oral Cancer.

Differential modulation of thermal preference after sensitization by optogenetic or pharmacological activation of heat-sensitive nociceptors

Assessment of an Allosteric Modulator of GIRK 1/2 in Preclinical Models of Cancer-Related Neuropathies to Alleviate Associated Mechanical Allodynia

Differences in electrophysiological properties of functionally identified nociceptive sensory neurons in an animal model of cancer-induced bone pain

STUDIES ON THE EXCITABILITY OF THE PRIMARY AFFERENT SENSORY NEURONS IN A RAT BONE CANCER PAIN MODEL